ProQR Therapeutics (PRQR) Operating Expenses (2013 - 2025)
ProQR Therapeutics recorded quarterly Operating Expenses of $123.1 million in Q4 2025, up 841.74% quarter-over-quarter from -$16.6 million in Q3 2025, and up 34.75% year-over-year from $91.4 million in Q4 2024.
ProQR Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $123.1 million for Q4 2025.
- In Q4 2025, Operating Expenses rose 34.75% year-over-year to $123.1 million; the TTM figure through Dec 2025 stood at $71.8 million (up 36.07% YoY), while the FY2025 annual figure was $69.6 million, up 30.22% from the prior year.
- Operating Expenses came in at $123.1 million for Q4 2025 at ProQR Therapeutics, up from -$16.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $127.9 million in Q4 2022 to a low of -$20.9 million in Q3 2022.
- A 5-year average of $8.4 million and a median of -$14.4 million in 2021 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses jumped 729.12% in 2022 and sank 69.5% in 2025, its largest moves.
- ProQR Therapeutics' Operating Expenses stood at -$20.3 million in 2021, then soared by 729.12% to $127.9 million in 2022, then slumped by 40.88% to $75.6 million in 2023, then increased by 20.83% to $91.4 million in 2024, then surged by 34.75% to $123.1 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $123.1 million, -$16.6 million, and -$18.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | 123.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 123.12 Mn |
| Sep 30, 2025 | -16.60 Mn |
| Jun 30, 2025 | -18.36 Mn |
| Mar 31, 2025 | -16.36 Mn |
| Dec 31, 2024 | 91.38 Mn |
| Sep 30, 2024 | -13.94 Mn |
| Jun 30, 2024 | -10.83 Mn |
| Mar 31, 2024 | -13.83 Mn |
| Dec 31, 2023 | 75.62 Mn |
| Sep 30, 2023 | -9.54 Mn |
| Jun 30, 2023 | -10.95 Mn |
| Mar 31, 2023 | -10.83 Mn |
| Dec 31, 2022 | 127.90 Mn |
| Sep 30, 2022 | -20.88 Mn |
| Jun 30, 2022 | -17.99 Mn |
| Mar 31, 2022 | -20.51 Mn |
| Dec 31, 2021 | -20.33 Mn |
| Sep 30, 2021 | -18.53 Mn |
| Jun 30, 2021 | -16.69 Mn |
| Mar 31, 2021 | -14.77 Mn |
| Dec 31, 2020 | -14.23 Mn |
| Sep 30, 2020 | -12.98 Mn |
| Jun 30, 2020 | -13.25 Mn |
| Mar 31, 2020 | -18.48 Mn |
| Dec 31, 2019 | -19.76 Mn |
| Sep 30, 2019 | -15.55 Mn |
| Jun 30, 2019 | -13.93 Mn |
| Mar 31, 2019 | -17.22 Mn |
| Dec 31, 2018 | -16.19 Mn |
| Sep 30, 2018 | -10.32 Mn |
| Jun 30, 2018 | -10.31 Mn |
| Mar 31, 2018 | 12,723.91 |
| Dec 31, 2017 | 13.23 Mn |
| Sep 30, 2017 | 11,725.96 |
| Jun 30, 2017 | -11.48 Mn |
| Mar 31, 2017 | 11.01 Mn |
| Dec 31, 2016 | -11.19 Mn |
| Sep 30, 2016 | -11.52 Mn |
| Jun 30, 2016 | -12.68 Mn |
| Mar 31, 2016 | -10.48 Mn |
| Dec 31, 2015 | -9.31 Mn |
| Sep 30, 2015 | -8.30 Mn |
| Jun 30, 2015 | -7.96 Mn |
| Mar 31, 2015 | -8.00 Mn |
| Dec 31, 2014 | -6.59 Mn |
| Sep 30, 2014 | -6.42 Mn |
| Mar 31, 2014 | -2.55 Mn |
| Dec 31, 2013 | -2.20 Mn |
| Sep 30, 2013 | -1.17 Mn |